Modeling the impact of cardio-pulmonary irradiation on overall survival in NRG Oncology trial RTOG 0617

Documenti analoghi

• Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer
  di: Bradley, Jeffrey D., et al.
  Pubblicazione: (2020)
• Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617
  di: Eaton, Bree R., et al.
  Pubblicazione: (2016)
• Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non–Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial
  di: Chun, Stephen G., et al.
  Pubblicazione: (2017)
• Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
  di: Bradley, Jeffrey D, et al.
  Pubblicazione: (2015)
• Multi-institutional Validation of a Knowledge-based Planning Model for Patients Enrolled on RTOG 0617: Implications for Plan Quality Controls in Cooperative Group Trials
  di: Kavanaugh, James A., et al.
  Pubblicazione: (2018)